CartiHeal’s Agili-C implant study aims to demonstrate the superiority of the Agili-C implant over the surgical standard of care for the treatment of cartilage or osteochondral defects. Credit: Dr Manuel González Reyes / Pixabay.

Israel-based CartiHeal has received breakthrough device designation from the Food and Drug Administration (FDA) for its Agili-C implant.

Agili-C is an implant for the treatment of cartilage lesions in arthritic and non-arthritic joints.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The FDA has launched its breakthrough device programme for medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.

It is intended to help patients receive more timely access to such medical devices by accelerating their development, assessment and review by the agency.

CartiHeal founder and CEO Nir Altschuler said: “We are extremely pleased that FDA granted the Agili-C implant breakthrough device designation.

“We look forward to working closely with FDA to expedite Agili-C’s review process, once the final IDE study results will be available in order to provide a promising treatment for millions of patients who suffer from cartilage defects and currently lack good treatment options.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A pivotal IDE clinical study is being conducted by CartiHeal to assess the superiority of Agili-C implant over the microfracture and debridement, which are the existing surgical standard of care.

The study has enrolled 251 subjects in 26 sites in the US, Europe and Israel. The subjects include patients with both mild to moderate osteoarthritis and focal defects without arthritic changes.

Final study results are expected next year.

In July, American orthobiologics company Bioventus invested $15m in CartiHeal.

As part of the financing round, the companies agreed on an option structure, under which Bioventus will acquire CartiHeal if the company secures the FDA approval for the Agili-C implant.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact